Pharmacological interventions such as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitors, selective cholesterol absorption inhibitors, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is), bile acid sequestrants, monoclonal antibodies, and nutritional supplements that promote of LDL-C excretion, and inhibitors of cholesterol synthesis and absorption are used in the traditional treatment of dyslipidemia [3]. The gene discussed is PCSK9; the disease is metabolic syndrome.